drughunter.com
< 1 minute read
Aug. 30, 2024

July 2024 Annotated Searchable Patent Table

Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

August 2024 Annotated Searchable Patent Table

We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.

Patent Highlights from January 2024: KRAS G12V, MAGL, and WRN Inhibitors, Nrf2 Degraders, and More

From WRN helicase to KRAS G12V, there were numerous hot targets of interest with patent applications published in January 2024. Here, we curated a searchable table comprising key information for more than 200 patents from January 2024 of potential interest to drug hunters, along with highlights from some of our favorites, including several degraders and molecules targeting Nrf2, KRAS G12V, MAGL, WRN, among others.

Patent Highlight: Tau-Targeting Heterobifunctional Degraders from Arvinas for Neurological Diseases

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

Patent Highlights: Synthetic Lethal MTA-Cooperative PRMT5 Inhibitors, TYK2 Degraders, Mutant p53 Reactivators, and More

February 2024 saw numerous notable patent disclosures aimed at a variety of therapeutic targets across different disease areas. The Drug Hunter team has compiled a searchable table that includes more than 200 patents of relevance to the drug discovery industry. Accompanying the table are detailed notes, as well as standout features from some of our top picks, including MTA-cooperative PRMT5 inhibitors, heterobifunctional TYK2 degraders, strategies for engaging and reactivating mutant p53, and more.

Patent Highlight: Highly Selective TREX1 Inhibitors from Constellation Pharmaceuticals

This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.